Micafungin in pediatrics: When one size does not fit all

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 4, 2008, Pages 463-469

  Ashouri, Negar ^a   Singh, Jasjit ^a   Arrieta, Antonio ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Antifungals; Aspergillus; Candidemia; Echinocandin; Fungal infections; Micafungin; Pediatric; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NIFEDIPINE; PYRROLE DERIVATIVE; RAPAMYCIN; STEROID; TACROLIMUS; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILD; CHILD CARE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT INFECTION; HUMAN; HYPERBILIRUBINEMIA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA; NONHUMAN; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; HUMANS; INFANT; INFANT, NEWBORN; LIPOPROTEINS; MYCOSES; TREATMENT OUTCOME;

ASPERGILLUS; CANDIDA;

EID: 44349110160     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.4.463     Document Type: Article

References (30)

1. Benjamin DK Jr, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002:21:227-34
2. Muller FM, Trussed A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002;161:563-74
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003:362:1142-51
4. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001;39(Suppl 1):55-66
5. Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001;183:2275-9
6. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002;48:78-81
7. Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002;46:3846-53
8. Ostrosky-Zeichner L, Rex JH, Pappas PG. et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54
9. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003;12:1313-33
10. Panackal AA, Imhof A, Hanley EW, et al. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006;12:403-8
11. Kontoyiannis DP, Lewis RE, May GS, et al. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002;45:406-7
12. Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003;47:1376-81
13. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
14. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007;51:3714-9
15. Seibel NL, Schwartz C, Arrieta AC, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24
16. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5
17. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL
18. Benjamin DK, Stoll BJ, Avory A, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopemental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92
19. Mycamine prescribing information (package insert). Astellas Pharmaceuticals. Available from: www.mycamine.com [Last accessed 20 February 2008]
20. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 2005;56:887-92
21. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-42
22. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003;47:1452-5
23. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802
24. Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16
25. Arrieta A, Queiroz-Telles F, Berezin E, et al. Micafungin versus liposomal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidaemia. 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 31 Mar-4 Apr, Munich, Germany [abstract 1732-85]
26. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61
27. Flynn P, Seibel N, Arrieta AC, et al. Treatment of invasive aspergillosis (IA) in pediatric patients with micafungin alone or in combination with other systemic antifungal agents. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sept 27-30; San Francisco, CA [abstract M-891]
28. Freire A, Arrieta AC, Stevenson P, Undre N. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL [abstract A-772]
29. Arrieta AC, Seibel N, Kovanda L, et al. Safety, efficacy and pharmacokinetics of micafungin in pediatric patients. 46th Interscience Conference on Andmicrobial Agents and Chemotherapy; 2006 Sept 27-30; San Francisco, CA [abstract M-876]
30. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dose of micafungin in premature neonates [abstract A-776a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17-20; Chicago, IL